Immunodeficiency 65 (IMD65) Cell Models for Research

Immunodeficiency 65 (IMD65) is a rare primary immunodeficiency disorder caused by mutations in the BCL11B gene. The exact prevalence is unknown, but it is considered extremely rare, with only a handful of cases reported worldwide. The condition presents with severe combined immunodeficiency (SCID) or Omenn syndrome-like features, including recurrent infections, failure to thrive, and autoimmune manifestations. Without early hematopoietic stem cell transplantation, the prognosis is poor. According to the National Cancer Institute (NCI), primary immunodeficiencies are associated with an increased risk of malignancies, particularly lymphomas, due to impaired immune surveillance. The 5-year survival for severe forms is low, but early diagnosis and treatment improve outcomes.

IMD65 is an ideal model for studying T-cell development and immune regulation. BCL11B is a critical transcription factor for T-cell lineage commitment and differentiation. The disease provides insights into fundamental mechanisms of hematopoiesis and immune tolerance. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Human Cell Atlas, offer expression data for BCL11B in various immune cell types. Open questions include the precise molecular pathways downstream of BCL11B and how specific mutations lead to distinct clinical phenotypes. Gene-edited cell models are essential to dissect these mechanisms.

Although IMD65 is not a cancer, it predisposes to malignancies. The major pathways affected include:

• • T-cell receptor (TCR) signaling: BCL11B regulates TCR signaling components, and its loss impairs T-cell activation and survival.
• • Notch signaling: BCL11B interacts with Notch pathway genes, and dysregulation can lead to aberrant T-cell development.
• • Apoptosis and cell cycle: BCL11B modulates expression of anti-apoptotic genes, and its loss may promote survival of abnormal cells.

These pathways are critical for immune function and tumor suppression.

Data from ClinVar and COSMIC databases.

BCL11B is a master regulator of T-cell development. Key deregulated networks include:

• • T-cell receptor (TCR) signaling: BCL11B regulates components of the TCR complex, and its loss impairs T-cell activation.
• • Notch signaling: BCL11B interacts with Notch pathway genes, and dysregulation can lead to aberrant T-cell development.
• • Cytokine signaling: BCL11B influences IL-7 receptor expression, critical for T-cell survival.
• • Transcriptional regulation: BCL11B represses genes that promote alternative lineages, such as NK cells and myeloid cells.

Organoids derived from thymic epithelial cells or hematopoietic stem cells can model T-cell development. Advantages include recapitulating 3D architecture and cell-cell interactions.

Animal models for IMD65 include:

• • Genetically engineered mouse models (GEMM): Bcl11b knockout mice exhibit severe T-cell developmental blocks, mimicking the human condition.
• • Patient-derived xenografts (PDX): Not commonly used for IMD65 due to rarity, but can be generated from patient hematopoietic cells.
• • Induced models: CRISPR-engineered mice with specific Bcl11b mutations are used to study genotype-phenotype correlations.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific BCL11B mutations. For example:

• • BCL11B knockout cell lines: Generated by introducing frameshift mutations in exon 3, leading to loss of protein expression. These models are useful for studying loss-of-function effects.
• • Point-mutation knock-in lines: Introducing known pathogenic mutations (e.g., R3X) allows modeling of specific clinical variants.

These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems. They are essential for functional studies and drug screening.

Knockout and knock-in lines are used to validate the role of BCL11B in T-cell development. For example, BCL11B knockout in hematopoietic stem cells impairs T-cell lineage commitment, confirming its essential role. These models also enable genome-wide CRISPR screens to identify synthetic lethal partners or downstream effectors.

Isogenic pairs (wild-type vs. BCL11B knockout) are used to screen for compounds that selectively target BCL11B-deficient cells. This is relevant for treating T-ALL, where BCL11B is overexpressed. Additionally, resistance mechanisms to immunotherapies can be studied by introducing BCL11B mutations in immune cells.

CRISPR-based synthetic lethality screens can identify genes that are essential only in BCL11B-deficient cells, providing potential therapeutic targets. These screens also help discover biomarkers for patient stratification.